Literature DB >> 29143180

Oxidative stress in adult growth hormone deficiency: different plasma antioxidant patterns in comparison with metabolic syndrome.

Antonio Mancini1, Chantal Di Segni2, Carmine Bruno2, Giulio Olivieri2, Francesco Guidi3, Andrea Silvestrini4, Elisabetta Meucci5, Patrick Orlando6, Sonia Silvestri6, Luca Tiano6, Alfredo Pontecorvi2.   

Abstract

BACKGROUND AND AIMS: Growth hormone deficiency (GHD) is a condition associated with increased cardiovascular risk and insulin-resistance. Oxidative stress (OS) could be a mechanism underlying both these phenomena. In order to investigate plasma antioxidant defenses in such condition, we evaluated adults with GHD, compared with controls and metabolic syndrome patients (MetS), studying plasma total antioxidant capacity (TAC) and coenzyme Q10 (CoQ10, lipophilic antioxidant) levels, both in its oxidized and reduced forms, correlating this data with metabolic and hormonal pattern.
MATERIALS AND METHODS: In this case-control study, 51 GHD, 36 controls, and 35 MetS were enrolled. An evaluation of hormonal and metabolic parameters was performed. TAC was measured using the system metmyoglobin -H202 and the chromogen ABTS, whose radical form is spectroscopically revealed; latency time (LAG) in the appearance of ABTS● is proportional to antioxidant in sample. CoQ10 was assayed by electrochemical method.
RESULTS: Despite HOMA index was higher in both GHD and MetS (2.2 ± 0.3 and 3.1 ± 0.3 vs. 1.2 ± 0.2 in controls), only in MetS we observed lower LAG levels (64.5 ± 3.1 s vs. 82.8 ± 5.8 in GHD and 80.6 ± 6.6 in controls), suggesting an increased consumption of antioxidants. LAG significantly correlated with uric acid only in MetS (r 2 = 0.65, p < 0.001), suggesting a different pattern of antioxidants. CoQ10 exhibited a trend toward lower levels in GHD, although not significant.
CONCLUSIONS: Our data indicate that GHD, although sharing with MetS various metabolic features, including increased HOMA levels, showed a different pattern of plasma antioxidants, suggesting inadequate reactivity toward radical production rather than an antioxidants consumption as in MetS.

Entities:  

Keywords:  Antioxidants; Coenzyme Q10; Insulin-resistance; Metabolic syndrome; Pituitary; Precision medicine

Mesh:

Substances:

Year:  2017        PMID: 29143180     DOI: 10.1007/s12020-017-1468-1

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  37 in total

Review 1.  Clinical aspects of coenzyme Q10: an update.

Authors:  Gian Paolo Littarru; Luca Tiano
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2005-11       Impact factor: 4.294

2.  Body composition and tissue distributions in growth hormone deficient adults before and after growth hormone treatment.

Authors:  L Lönn; G Johansson; L Sjöström; H Kvist; A Odén; B A Bengtsson
Journal:  Obes Res       Date:  1996-01

3.  Antioxidant enzymes, free-radical damage, and response to paraquat in liver and kidney of long-living growth hormone receptor/binding protein gene-disrupted mice.

Authors:  S J Hauck; J M Aaron; C Wright; J J Kopchick; A Bartke
Journal:  Horm Metab Res       Date:  2002-09       Impact factor: 2.936

4.  Increased lipid peroxidation in adult GH-deficient patients: effects of short-term GH administration.

Authors:  M Scacchi; E Valassi; A I Pincelli; L M Fatti; F Pecori Giraldi; P Ascoli; R Viarengo; B Cestaro; F Cavagnini; R Cazzola
Journal:  J Endocrinol Invest       Date:  2006-11       Impact factor: 4.256

5.  Increased Interleukin-6 levels in pituitary-deficient patients are independently related to their carotid intima-media thickness.

Authors:  M Leonsson; J Hulthe; G Johannsson; O Wiklund; J Wikstrand; B A Bengtsson; J Oscarsson
Journal:  Clin Endocrinol (Oxf)       Date:  2003-08       Impact factor: 3.478

6.  High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults.

Authors:  J O Johansson; K Landin; L Tengborn; T Rosén; B A Bengtsson
Journal:  Arterioscler Thromb       Date:  1994-03

7.  Growth hormone-releasing peptide-2 suppresses vascular oxidative stress in ApoE-/- mice but does not reduce atherosclerosis.

Authors:  Jane S Titterington; Sergiy Sukhanov; Yusuke Higashi; Charlotte Vaughn; Cyril Bowers; Patrice Delafontaine
Journal:  Endocrinology       Date:  2009-10-09       Impact factor: 4.736

8.  Mitochondrial protection by low doses of insulin-like growth factor- I in experimental cirrhosis.

Authors:  Raquel Pérez; María García-Fernández; Matías Díaz-Sánchez; Juan E Puche; Gloria Delgado; Marian Conchillo; Jordi Muntané; Inma Castilla-Cortázar
Journal:  World J Gastroenterol       Date:  2008-05-07       Impact factor: 5.742

Review 9.  Cardiovascular risk factors in hypopituitary GH-deficient adults.

Authors:  Johan Verhelst; Roger Abs
Journal:  Eur J Endocrinol       Date:  2009-08-14       Impact factor: 6.664

10.  Growth hormone replacement therapy regulates microRNA-29a and targets involved in insulin resistance.

Authors:  Artur Galimov; Angelika Hartung; Roman Trepp; Alexander Mader; Martin Flück; Axel Linke; Matthias Blüher; Emanuel Christ; Jan Krützfeldt
Journal:  J Mol Med (Berl)       Date:  2015-07-23       Impact factor: 4.599

View more
  3 in total

1.  Can plasma antioxidants prevent DNA damage in oxidative stress condition induced by growth hormone deficiency? A pilot study.

Authors:  Antonio Mancini; Francesco Guidi; Carmine Bruno; Flavia Angelini; Edoardo Vergani; Paola Lanza; Alvaro Mordente; Elisabetta Meucci; Andrea Silvestrini
Journal:  PLoS One       Date:  2021-04-01       Impact factor: 3.240

2.  LEAP-2/ghrelin interplay in adult growth hormone deficiency: Cause or consequence? A pilot study.

Authors:  Edoardo Vergani; Carmine Bruno; Cesare Gavotti; Luigi Simone Aversa; Maria Martire; Antonio Mancini; Diego Currò
Journal:  IUBMB Life       Date:  2021-05-28       Impact factor: 3.885

Review 3.  Effects of adult growth hormone deficiency and replacement therapy on the cardiometabolic risk profile.

Authors:  Balázs Ratku; Veronika Sebestyén; Annamária Erdei; Endre V Nagy; Zoltán Szabó; Sándor Somodi
Journal:  Pituitary       Date:  2022-02-01       Impact factor: 4.107

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.